Steven Li
Languages
English简体中文
Contact
Explore website

Pharmaceutical Insights · Steven Li (李一青)

Singapore Pharma: Registration and Dealer Roles

A first-discussion guide for Singapore therapeutic-product partnerships: map the registration applicant, importer and wholesaler before assigning responsibilities.

Prepare a non-confidential product partnership brief

“We have a local partner” is not a complete project description. For an initial Singapore therapeutic-product discussion, map the product, the proposed companies and their intended activities before deciding who will prepare which evidence.

1. Identify the proposed registration applicant

HSA says a therapeutic-product registration applicant must be a local company registered with ACRA. Its registration overview treats application type, evaluation route and dossier format as separate preparation questions. [1]

For the first discussion, record the exact product and presentation, proposed applicant and current stage. Write “to confirm” where the company or role has not yet been agreed. A proposed commercial relationship should not be described as a completed registration arrangement.

2. Map import and wholesale separately

HSA uses activity-based dealer licensing. Its overview identifies TPIL for import and TPWL for wholesale, with applicable GDP compliance. It also explains that when a product registrant outsources import and wholesale, including invoicing, the relevant licensing and GDP requirements apply to the outsourced company; the registrant need not hold those licences itself for those outsourced activities. [2]

Use that distinction to ask who is actually expected to import, store, invoice and supply the product. This is a role-mapping exercise, not confirmation that any named company holds the required permissions.

For an importer’s licence application, HSA’s document list includes an authorisation letter from the product registrant when the products are not registered under the applicant company. At the scoping stage, identify the registrant and who can arrange that letter; confirm current requirements with the responsible licensing team before applying. [6]

3. Bring a short role map to the meeting

  • Product: identify the product, presentation, intended Singapore use and current project stage.
  • Companies: name the proposed applicant and the businesses expected to perform each activity.
  • Evidence: list the dated official record or controlled document needed to confirm each claim.
  • Open point: assign an owner and next action where the role, scope or evidence remains unresolved.

Keep proposed commercial rights in a separate discussion from regulatory roles. Do not infer a licence, a registration, supply availability or authority to negotiate from a catalogue entry or an overseas product record.

4. Agree the dossier handover before submission

HSA accepts ICH CTD or ACTD organisation, with eCTD available for ICH CTD. Its dossier page requires English electronic documents and searchable, flattened, unencrypted PDFs. These are formal submission requirements, not instructions to send confidential files through an initial inquiry. [3]

Packaging configuration also needs an explicit check. HSA’s 30 September 2026 update revised Appendix 17 on deciding between an individual registration and multiple packaging configurations under one registration, effective that day. Record each intended presentation and have the responsible regulatory team confirm the appropriate submission structure against current guidance. [5]

HSA’s 31 March 2026 update introduced, from 1 June 2026, an applicant letter declaring no known quality defects that would require amendments or updates to the submitted CMC package. Confirm the current guidance and its application to the actual submission with the responsible regulatory and quality teams. [4]

As a practical coordination step, record:

  • Document owner: who maintains the current dossier and can explain its revision history?
  • Preparation and review: who prepares the submission package, and who checks its content and technical format?
  • Open changes: which unresolved quality findings or pending updates could affect the planned dossier version?
  • Controlled handover: what files may be shared, with whom, through which agreed channel, and after which permissions are confirmed?

This working list is not an HSA checklist. Holding a dossier copy does not establish rights to use it, completeness, submission acceptance or product approval.

5. Leave the scope visible

Ask the relevant Singapore regulatory and quality specialists to confirm the actual pathway before committing to a work plan. Keep the initial exchange non-confidential; detailed dossiers and agreements belong in an agreed controlled review channel.

Frequently asked questions

What should an initial partner-role map contain?

Start with the product, proposed companies, intended activities, evidence needed and the owner of each unresolved question.

Does this guide confirm that a particular partner is qualified?

No. It provides a way to organise an initial discussion. The actual company, product, activity and supporting evidence still need review.

Official sources

  1. HSA — Registration process: overview (updated 4 May 2026)
  2. HSA — Importer, wholesaler and manufacturer licences (updated 31 October 2026)
  3. HSA — Application dossier (updated 20 May 2026)
  4. HSA — Regulatory updates on therapeutic product registration (31 March 2026)
  5. HSA — Regulatory updates for therapeutic product registration (30 September 2026)
  6. HSA — Apply for an importer, wholesaler or manufacturer licence (updated 31 October 2026)

Prepare the eCTD handover

HSA accepted eCTD for therapeutic-product regulatory dossier submissions from 1 April 2026. It specifies SG-HSA eCTD version 1.1 as the official standard for all eCTD submissions. Online technical files cover defined lists, the document matrix and the submission type matrix, supporting real-time access and validation.

HSA presents eCTD as an accepted submission option. Companies may continue their current non-eCTD submission modes, while HSA strongly encourages transition to eCTD.

For handover planning, consider these author-developed coordination questions. Who is the named dossier owner for the planned eCTD package? Who will take responsibility for publishing the package and coordinating its technical review? Who will check the current technical resources before handover and record which versions the team used? These questions are editorial preparation advice.

Official source
HSA eCTD regulatory update

All insights →

Separate product records, rights and handover

Read overseas-registration evidence within scope

Product registration · In-licensing · Market partnerships

Prepare a non-confidential product partnership brief

Open the product cooperation workspace